Menu
English English
Deutsch Deutsch English English
Sign up
sharewise sharewise
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise
Watchlist

General Electric Co. Stock

Price
Target price
€6.22

€6.22

-2.420%
-0.181
-2.420%
€16.24

€16.24

 
Buy 8 Sell 0
Buy 8
Sell 0
03.04.20 / Tradegate WKN: 851144 / Symbol: GE / Name: General Electric / Stock / Industriekonglomerate / Large Cap
Latest predictions
€10.41
08.11.19
buy
-
05.11.19
buy
€11.73
04.08.19
buy
€13.53
11.05.19
buy
€16.24
25.01.19
buy
€20.30
12.01.19
buy
Your prediction

General Electric Co. Stock

A loss of -2.420% shows a downward development for General Electric Co..
General Electric Co. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
Based on the current price of €6.22 the target price of €16.00 shows a potential of 157.193% for General Electric Co. which would more than double the current price.

Comments

Published 13.11.17
Prediction Buy
Perf. (%) -50.340%
Target price 19.844
Change

Kauf für Erholung

Der Wert hat endlich Unterstützung seine technische Erholung zu starten ... und eine neue Strategie

Letue35 
0
Report
13.11.17
Published 02.11.18
Prediction Buy
Perf. (%) -50.340%
Target price 19.844
Change

(Laufzeit überschritten)

Letue35 
0
Report
02.11.18
Published 08.11.19
Prediction Buy
Perf. (%) -40.010%
Target price 10.410
Change

Buy with target price 10.41

yaichenbaum 
1
Report
08.11.19
Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about General Electric Co. Stock

New thread

News

GE Healthcare Announces U.S. FDA Approval of Macrocyclic MRI Contrast Agent Clariscan™ (gadoterate meglumine) Injection for Intravenous Use


The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio for U.S. patients and

BusinessWire_EN
0 08.11.19
DGAP-News: General Electric Company: GE Files Proxy Materialshttp://upload.wikimedia.org/wikipedia/commons/e/e4/General_electric.jpg: Thomas Edison [Public domain], via Wikimedia Commons
DGAP-News: General Electric Company: GE Files Proxy Materials

DGAP-News: General Electric Company: GE Files Proxy Materials

eqs_en
0 13.03.20
DGAP-News: General Electric Company: GE Files Proxy Statementhttp://upload.wikimedia.org/wikipedia/commons/e/e4/General_electric.jpg: Thomas Edison [Public domain], via Wikimedia Commons
DGAP-News: General Electric Company: GE Files Proxy Statement

DGAP-News: General Electric Company: GE Files Proxy Statement

eqs_en
0 13.03.20
DGAP-News: General Electric Company: GE Files Form 10-Khttp://upload.wikimedia.org/wikipedia/commons/e/e4/General_electric.jpg: Thomas Edison [Public domain], via Wikimedia Commons
DGAP-News: General Electric Company: GE Files Form 10-K

DGAP-News: General Electric Company: GE Files Form 10-K

eqs_en
0 13.03.20